Smith Nicholas Conrad
PRESIDENT AND CFO
Smith Nicholas Conrad has filed 3 SEC Form 4 filings (8 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Oct 5, 2026.
On the most recent filing, Smith Nicholas Conrad is listed as PRESIDENT AND CFO at Alto Neuroscience, Inc. Inside the rolling window, Smith Nicholas Conrad reported no open-market purchases and 2 open-market sales totaling $3.6M in ANRO. The largest disclosed transaction in the window is a sale of 110,830 ANRO shares on Sep 29, 2026, worth $2.9M.
Companies traded
Other insiders at ANRO
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$3.6M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Smith Nicholas Conrad made?
Smith Nicholas Conrad has filed 3 SEC Form 4 filings (8 transaction rows) across 1 company since 2026.
Which companies does Smith Nicholas Conrad trade?
Smith Nicholas Conrad has filed SEC Form 4 disclosures for 1 company, including ANRO.
When was Smith Nicholas Conrad's most recent SEC Form 4 filing?
Smith Nicholas Conrad's most recent SEC Form 4 filing on Tracefour is dated Oct 5, 2026.
What is Smith Nicholas Conrad's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Smith Nicholas Conrad is listed as PRESIDENT AND CFO.
What is Smith Nicholas Conrad's total buy and sell value in the current window?
Inside the rolling retention window, Smith Nicholas Conrad bought $0 and sold $3.6M based on SEC Form 4 filings.
What was Smith Nicholas Conrad's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 110,830 ANRO shares on 2026-09-29, worth $2.9M, per SEC Form 4 filings.